CPVT trial INFORMATION

Catecholaminergic **P**olymorphic **V**entricular **T**achycardia (**CPVT**) can cause an abnormal heart rhythm (arrhythmia). This new trial is now recruiting to test the impact of an investigational study drug on arrhythmia in people living with CPVT.

What will the trial **investigate?**

The trial will investigate how safe, tolerable, and effective the study drug, CRD-4730, is in adult patients with CPVT. Participants with CPVT will be recruited for the trial lasting approximately 14 weeks, plus up to 21 days of screening (a period before the trial to make sure participants are eligible).

Who can **participate?**

- Adult men or women, aged 18 years or above
- People in good health, with a confirmed CPVT diagnosis
- People who are not pregnant and not planning to conceive during the trial

The trial involves **2 different doses** of the **study drug** (CRD-4730) and **1 dose** of a **placebo**.

What **tests are involved?**

At clinic

- **Four treadmill** or **cycle machine**-based **exercise stress tests** will be performed.
- Participants will provide **blood** and **urine** samples at **each visit**.

At home

- Participants will perform **daily electrocardiogram (ECG)** recordings **at home** on a portable device to monitor heart activity once they start taking the **study drug**.

Interested? **Next steps...**

1. Speak to a member of your care team to find out more information.
2. Screening process - find out more below.
3. If you are eligible, initiation of the first treatment period of the trial.

What is involved in the screening process?

Screening ensures volunteers are eligible for the trial, e.g., a confirmed CPVT diagnosis, in good health, and not pregnant. Screening occurs during a clinic visit and includes blood and urine samples, an exercise stress test, possible genetic testing (to confirm CPVT), and a pregnancy test (females only).

Participation involves attending 8 clinic visits, with travel and accommodation costs reimbursed. Participants will also be contributing to important research which may support the CPVT community in the future.

CARDURION PHARMA

The following institutions are currently accepting inquiries for trial participation:

Duke University Medical Center | Durham, NC
Trial Contact: andrea.osunabastidas@duke.edu

University of California, San Francisco | San Francisco, CA
Trial Contact: Brynn.Sofro@ucsf.edu

University of Wisconsin-Madison, Division of Cardiovascular Medicine | Madison, WI
Trial Contact: cvmstudyteam@medicine.wisc.edu

For additional information, please visit https://clinicaltrials.gov/study/NCT06658899